Triplet Therapeutics harnesses human genetic insights to develop treatments for repeat expansion disorders by targeting the DNA damage response pathway. The company is advancing antisense oligonucleotide (ASO) and small interfering RNA (siRNA) candidates designed to precisely knock down DDR components that drive repeat expansion. Its approach targets disease drivers upstream of current therapies with the goal of halting onset and progression across multiple disorders, including Huntington’s disease, myotonic dystrophy and spinocerebellar ataxias. Triplet has assembled a senior management team and a Scientific Advisory Board of leading investigators in the field. The company will use recent financing to progress its first development candidates into IND-enabling studies and to advance natural history studies to inform its clinical plans. Triplet was founded in 2018 and is headquartered in Cambridge, Mass.

Total raised

$49M

Funding rounds

1

Latest round

Series A

Latest activity

Dec 2019